In this issue:
CCNE1 amplification status may be a biomarker in HGSOC
Adavosertib has activity in EOC harbouring CCNE1 amplification
Olaparib combo maintenance prolongs PFS regardless of BRCA1/2 mutation location
Better diet linked to improved survival in ovarian cancer patients
Do bone loss medications reduce the risk of ovarian cancer?
Proteomic signature may allow early detection of high-grade disease
Do inflammatory markers have any prognostic capabilities in ovarian cancer?
Genetic predisposition to cancer does not impact the chemoprotective effect of aspirin
Assessing the need for VTE prophylaxis during neoadjuvant chemotherapy
Please login below to download this issue (PDF)